Investors interested in U.S. cannabis companies face a daunting challenge as just finding the stocks is hard, Bill Alpert writes in this week's edition of Barron's. Companies can't list on the Nasdaq (NDAQ) or New York Stock Exchange (ICE), while companies that sell only in Canada, like Canopy Growth (CGC), can list in the U.S. and tap deeper-pocketed investors, the report notes. The U.S. companies have disclosed investment risks ranging from federal investigations to allegations of self-dealing, alongside thin trading in Canada's market, but potential problems do not seem to be reflected in U.S. cannabis stock prices, which carry a hefty collective market valuation of $14B, despite modest revenues and the ferocious cash-burn rates at loss-making start-ups, the author contends. Reference Link
